Phase i trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 4, 2015, Pages 739-750

  Mukai, Hirofumi ^a   Masuda, Norikazu ^b   Ishiguro, Hiroshi ^c   Mitsuma, Ayako ^d   Shibata, Takashi ^d   Yamamura, Jun ^e   Toi, Masakazu ^c   Watabe, Aiko ^f   Sarashina, Akiko ^f   Uttenreuther Fischer, Martina ^g   Ando, Yuichi ^d  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

^e Sakai City Medical Center   (Japan)

^f NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Afatinib; Dose escalation; Japanese; Phase I; Vinorelbine

Indexed keywords

AFATINIB; AMYLASE; NAVELBINE; STEROID; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VINBLASTINE;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DECREASED APPETITE; DERMATITIS ACNEIFORM; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; INFUSION SITE EXTRAVASATION; INTERSTITIAL LUNG DISEASE; JAPANESE (PEOPLE); LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; OPEN STUDY; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SOLID TUMOR; STEROID THERAPY; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR SHRINKAGE; VASCULITIS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; DRUG MONITORING; JAPAN; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PATIENT DROPOUTS; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ERBB RECEPTORS; FEMALE; HUMANS; JAPAN; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASMS; PATIENT DROPOUTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TUMOR BURDEN; VINBLASTINE;

EID: 84942194047     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2826-4     Document Type: Article

References (24)

1. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117:2051-2058
2. Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12:553-563
3. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711
4. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350
5. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334
6. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213-222
7. Yang JC-H, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu Y-L (2014) Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies [LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)] comparing afatinib with chemotherapy (CT). J Clin Oncol 32:[abstract 8004]
8. European Medicines Agency (2013) Afatinib - European Public Assessment Report (summary). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/human-med-001698.jsp&mid=WC0b01ac058001d124. Accessed 7 April 2014
9. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf. Accessed 4 Feb 2013
10. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, Jr.; de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, LUX-H&N 1 investigators (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583-594
11. Goss GD, Felip E, Cobo M, Lu S, Syrigos KN, Lee KH, Göker, E.; Georgoulias V, Li W, Isla D, Morabito A, Guclu SZ, Min YJ, Ardizzoni A, Gadgeel S, Love J, Chand V, Soria J (2014) A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). Ann Oncol 25:[abstract iv426]
12. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133:1057-1065
13. Bahleda R, Soria J, Berge Y, Massard C, Wind S, Uttenreuther-Fischer MM, Fleischer F, De-Montserrat H, Solca F, Tschoepe I, Delord J (2011) Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. J Clin Oncol 29:[abstract 2585]
14. Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13:1065-1071
15. ® (vinorelbine tartrate) injection-prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/20388s014lbl.pdf. Accessed 14 May 2014
16. MHRA (2010) Vinorelbine 10 mg/mL concentrate for solution for infusion UK Public Assessment Report. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con099695.pdf. Accessed 19 Jan 2015
17. Pharmaceuticals and Medical Devices Agency J (2005) New drugs approved in FY 2005. http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2005.pdf. Accessed 19 Jan 2015
18. Hollebecque A, Bahleda A, Bergé Y, Massard C, Uttenreuther-Fischer M, de Mont-Serrat H, Tschoepe I, Schnell D, Soria J-S, Delord J-P (2013) A phase I trial assessing the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumours. Eur J Cancer 49:[abstract 892]
19. Harbeck N, Huang C-S, Hurvitz SA, Yeh D-C, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen S, Goeldner RG, Lahogue A, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M (2014) Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1. Presented at San Antonio Breast Cancer Symposium, 9-13 Dec 2014. Abstract P5-19-01
20. European Medicines Agency (2014) Giotrif - European Public Assessment Report (product information). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002280/WC500152392.pdf. Accessed 19 Nov 2014
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
22. European Medicines Agency (2013) Giotrif - summary of product characteristics, annex 1. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002280/WC500152392.pdf. Accessed 19 Nov 2014
23. Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 5:179-184
24. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31:3335-3341